Genolution

Genolution P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Genolution (225220.KQ) as of Oct 22, 2026 is -4.39. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -2.40 — a change of 82.70% (lower).

P/FCF

-4.39

YoY

82.70%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genolution is 2025 -4.39 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Genolution was 2024 -2.40 . It decreases by 82.70% lower compared to the previous year.

The Genolution P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-11.78 KRW
Jan 1, 2019
-10.14 KRW
Jan 1, 2020
0.88 KRW
Jan 1, 2021
1.59 KRW
Jan 1, 2022
-3.64 KRW
Jan 1, 2023
-4.08 KRW
Jan 1, 2024
-2.40 KRW
Jan 1, 2025
-4.39 KRW
The Genolution P/FCF history
YEARP/FCFYoY
-4.39+82.70%
-2.40-41.12%
-4.08+12.16%
-3.64-329.07%
1.59+81.00%
0.88-108.65%
-10.14-13.92%
-11.78-94.80%
-226.31+165.25%
-85.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genolution is -4.39 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genolution changed from -2.40 to -4.39, representing a 82.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Genolution since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genolution

All Key Metrics — Genolution